Skip to main content

Year: 2022

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of...

Continue reading

VICTORY RESOURCES CORPORATION ANNOUNCES SHARE CONSOLIDATION AND NAME CHANGE TO VICTORY BATTERY METALS CORP.

Vancouver, Dec. 22, 2022 (GLOBE NEWSWIRE) — VANCOUVER, BC, CANADA (December 22, 2022) – Victory Resources Corporation (CSE: VR) (FWB: VR61) (OTC: VRCFF) (“Victory” or the “Company”) is pleased to announce that it intends to proceed with a name change to “Victory Battery Metals Corp.” (the “Name Change”) and consolidation of its common shares on the basis of three (3) pre-consolidation common shares for one (1) post-consolidation common share of the Company (the “Share Consolidation”). The Board of Directors approved the Name Change and Share Consolidation on December 16, 2022. The Company currently has 127,611,222 common shares issued and outstanding.  Accordingly, once the Share Consolidation is effective, the Company will have 42,537,074 common shares issued and outstanding, assuming there are no other changes in the issued capital...

Continue reading

R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference

MURRAY, Utah, Dec. 22, 2022 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 41st Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2023, at 7:30 am PT. A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 30 days following the live webcast. About R1 RCM R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s...

Continue reading

Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule. The clinical remission (CR) rate...

Continue reading

Petrus Resources Announces Monthly Activity Update

CALGARY, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce the most recent version of the Company’s monthly activity update can be found on the Company’s website at https://www.petrusresources.com/monthlyupdates. ABOUT PETRUSPetrus is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions and risk-managed exploration in Alberta. FOR FURTHER INFORMATION PLEASE CONTACT:Ken Gray President and Chief Executive Officer T: 403-930-0889 E: kgray@petrusresources.com

Continue reading

Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has closed a Regulation S private placement (the “Transaction”) for expected aggregate gross proceeds of $220,585. The Company currently intends to use the net proceeds from the Transaction for general working capital purposes. On December 21, 2022,  the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 14 investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in the Transaction (i) 176,462 shares of the Company’s Series D Convertible Preferred Stock (the “Preferred...

Continue reading

Jianzhi Education Technology Group Company Limited Reports First Half 2022 Financial Results

BEIJING, Dec. 22, 2022 (GLOBE NEWSWIRE) — Jianzhi Education Technology Group Company Limited (the “Company” or “Jianzhi”) (NASDAQ: JZ), a leading provider of digital educational content in China, today announced its financial results for the first half of 2022.Net revenues were RMB260.3 million ($38.8 million) for the first six months of 2022, compared to RMB276.4 million during the same period in 2021.Gross profit was RMB40.0 million ($6.0 million) for the first six months of 2022, compared to RMB71.7 million during the same period in 2021.Net loss for the first half 2022 was RMB2.9 million ($0.4 million) for the first six months of 2022, compared to net income of RMB43.8 million during the same period in 2021.Yong Hu, CEO of the Company commented: “In the first half of 2022, our team worked relentlessly and managed to...

Continue reading

Firm Capital Property Trust Closes Two Previously Announced Transactions

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”) (TSX : FCD.UN) is pleased to provide the following update to a previously announced acquisition and disposition: $6.2 MILLION ACQUISITION OF TWO EDMONTON INDUSTRIAL PROPERTIESThe $6.2 million acquisition in the existing Edmonton Joint Venture Partnership of a 50% interest in two multi-tenant industrial properties with a combined area of 68,000 square feet, located in Edmonton, Alberta (the “Properties”) has officially closed. The Properties offer excellent access to major vehicular and rail transportation infrastructure. The Properties are a short drive to both downtown Edmonton, the Edmonton International Airport and in close proximity to the Trust’s existing Edmonton Industrial properties. The Properties have a total of 19 units with...

Continue reading

CENTOGENE Reports Second Quarter and First Half 2022 Financial Results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook. The quarterly and half year results are compared to the same periods in the prior year, unless otherwise specified, and reflect revisions as described below. Second Quarter 2022 – Financial HighlightsOverall revenues increased by 21.6% year-over-year to €11.2 million Diagnostics segment revenues increased by 18.3% year-over-year to €7.5 million Pharmaceutical segment (“Pharma”) revenues increased by 29% year-over-year to €3.7 million Net loss from continuing operations...

Continue reading

Copper Lake Resources Announces Closing of Second and Final Tranche of Previously Announced Non-Brokered Private Placement

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) — Copper Lake Resources Ltd. (TSX-V: CPL, Frankfurt: WOI, OTC: WTCZF) (“Copper Lake” or the “Company”) is pleased to announce that it has closed the second and final tranche (the “Final Tranche”) of its non-brokered private placement offering of Flow-Through Units (the “Units”) previously announced on December 2, 2022 (the “Private Placement”). In conjunction with the closing, the Company issued an additional 6,176,472 Units for gross proceeds of $525,000, resulting in a total issuance for the Private Placement of 15,097,472 Units for gross proceeds of $1,283,285. Terr MacDonald, CEO of Copper Lake commented, “We are very pleased to have successfully raised these funds as the last few months have been very challenging for junior mining companies in the equity markets. We are now well positioned...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.